Publication | Closed Access

Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma

Hematological MalignancyMetaphase SpreadsMedicineHematologyPathologyMonosomy 13OncologyRadiation OncologyMyelopoiesisDexamethasone TreatmentHealth Sciences